- Home
- LBTYB vs TNGX Comparison
LBTYB vs TNGX Comparison
Compare LBTYB & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYB | TNGX |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.1B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LBTYB | TNGX |
|---|---|---|
| Price | $11.94 | $22.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $44.88 |
| AVG Volume (30 Days) | 25.1K | ★ 3.6M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $11,541,500,000.00 | $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.51 | N/A |
| P/E Ratio | $12.29 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $10.20 | $6.69 |
| 52 Week High | $29.01 | $34.39 |
Technical Indicators
Market Signals| Indicator | LBTYB | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 43.65 |
| Support Level | $11.80 | $21.63 |
| Resistance Level | $13.21 | $25.93 |
| Average True Range (ATR) | 0.55 | 1.44 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 34.64 | 28.76 |
Price Performance
Historical ComparisonAbout LBTYB Liberty Global Ltd. Class B
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.